Literature DB >> 27311685

A simple LC/MRM-MS-based method to quantify free linker-payload in antibody-drug conjugate preparations.

Wesley Zmolek1, Stefanie Bañas1, Robyn M Barfield1, David Rabuka1, Penelope M Drake2.   

Abstract

Antibody-drug conjugates represent a growing class of biologic drugs that use the targeted specificity of an antibody to direct the localization of a small molecule drug, often a cytotoxic payload. After conjugation, antibody-drug conjugate preparations typically retain a residual amount of free (unconjugated) linker-payload. Monitoring this free small molecule drug component is important due to the potential for free payload to mediate unintended (off-target) toxicity. We developed a simple RP-HPLC/MRM-MS-based assay that can be rapidly employed to quantify free linker-payload. The method uses low sample volumes and offers an LLOQ of 10nM with 370pg on column. This analytical approach was used to monitor free linker-payload removal during optimization of the tangential flow filtration manufacturing step.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  ADC; Antibody-drug conjugate; Free drug; MRM; Multiple-reaction monitoring

Mesh:

Substances:

Year:  2016        PMID: 27311685     DOI: 10.1016/j.jchromb.2016.05.055

Source DB:  PubMed          Journal:  J Chromatogr B Analyt Technol Biomed Life Sci        ISSN: 1570-0232            Impact factor:   3.205


  4 in total

Review 1.  Challenges and new frontiers in analytical characterization of antibody-drug conjugates.

Authors:  Anil Wagh; Hangtian Song; Ming Zeng; Li Tao; Tapan K Das
Journal:  MAbs       Date:  2018-01-05       Impact factor: 5.857

2.  Antibody-Drug Conjugates Targeting the Urokinase Receptor (uPAR) as a Possible Treatment of Aggressive Breast Cancer.

Authors:  Efrat T Harel; Penelope M Drake; Robyn M Barfield; Irene Lui; Shauna Farr-Jones; Laura Van't Veer; Zev J Gartner; Evan M Green; André Luiz Lourenço; Yifan Cheng; Byron C Hann; David Rabuka; Charles S Craik
Journal:  Antibodies (Basel)       Date:  2019-11-05

3.  CRISPR-Cas9 screens identify regulators of antibody-drug conjugate toxicity.

Authors:  C Kimberly Tsui; Robyn M Barfield; Curt R Fischer; David W Morgens; Amy Li; Benjamin A H Smith; Melissa Anne Gray; Carolyn R Bertozzi; David Rabuka; Michael C Bassik
Journal:  Nat Chem Biol       Date:  2019-08-26       Impact factor: 15.040

4.  Antibody-drug conjugate library prepared by scanning insertion of the aldehyde tag into IgG1 constant regions.

Authors:  Betty C B Huang; Yun Cheol Kim; Stefanie Bañas; Robyn M Barfield; Penelope M Drake; Igor Rupniewski; William E Haskins; David Rabuka
Journal:  MAbs       Date:  2018-09-25       Impact factor: 5.857

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.